Innovating GLP-1 Mono-Agonist Development for Refined Efficacy & Safety to Expand Patient Accessibility
Time: 10:30 am
day: Day One
Details:
- Enhancing peptide stability and half-life for reduced dosing frequency to improve patient convenience for greater adherence
- Minimizing gastrointestinal side effects for improved patient comfort to increase treatment acceptance for wider clinical adoption
- Exploring novel delivery technologies for alternative administration routes to broaden patient access for diverse therapeutic needs
